Pronucleon TM Amplified Misfolded Protein Diagnostic Assay (AMP-D) Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc., Rockville, MD.

Slides:



Advertisements
Similar presentations
Distinctive characteristics
Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section
Use of PMCA for Biochemical Diagnosis of Prion Diseases Claudio Soto, PhD Dept of Neurology, University of Texas Medical Branch and Amprion Inc.
Removal of Prions by Plasma Fractionation Processes
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
® Bovine Derived Products are Safe TSE Advisory Committee Serologicals Corporation February 2004.
Copyright © 2005 Pearson Education, Inc. publishing as Benjamin Cummings Concept 5.4: Proteins have many structures, resulting in a wide range of functions.
Vironostika® HIV-1 Plus O Microelisa System
Nucleic Acid Extraction Control in Real-Time PCR Assays Steve Hawkins Senior Global Product Manager Bioline.
PRIONS Defn: small proteinaceous infectious particles that resist inactivation by procedures that modify viruses and nucleic acids.
1 PROTEINS. 2 Proteins Proteins are polymers made of monomers called amino acids (aka building blocks) 8-10 we can not make. All proteins are made of.
Mouse Prion Protein Domain PrP( ) Andreas Razen Geometric Computations in Molecular Biology 2 May 2007.
1 September, 2004 Chapter 5 Macromolecular Structure.
Assays Molecular Diagnostics CSULA. What’s a molecular diagnostic assay? n A laboratory test for the presence or absence of a particular type of molecule.
L and D isomers of amino acids. Ionization state as a function of pH.
CLINICAL ASPECTS OF BIOCHEMISTRY NEURODEGENERATIVE DISEASES Prion diseases Alzheimer's disease.
TMA Assay for Detection of West Nile Virus BPAC Meeting - March 13, 2003 Cristina Giachetti, Ph.D. J.Linnen; A.Broulik; W. Wu; J.Cline; M.Lewis; G.Dennis;
HIV Testing Quality Assurance and Quality Control
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
Food and Drug Administration Food and Drug Administration Center for Biologics Evaluation and Research Biological Response Modifiers Advisory Committee.
Holly Allen CREUTZFELDT-JAKOB DISEASE.  Human equivalent of mad cow disease  Rare, degenerative, fatal disease  Approximately 1 case per million per.
TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical.
Biotechnology in Medicine Chapter 12.
Lecture 4-Kumar Protein Structure and Function 1.
A carboxylated Zn-phthalocyanine inhibits the fibril formation of Alzheimer’s amyloid β peptide Atsushi Nagai Dept. Laboratory Medicine Shimane University.
Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.
A protein’s function depends on its specific conformation (shape) A functional proteins consists of one or more polypeptides that have been precisely twisted,
Protein Structure Stryer Short Course Chapter 4. Peptide bonds Amide bond Primary structure N- and C-terminus Condensation and hydrolysis.
Prions: Proteins Gone Bad
Founders With the support of Results4th Call for Projects NeuroPrion2010 Salzburg.
Prions and Protein Misfolding BICH 107 GENE 105. Kuru Discovered in Papua New Guinea in early 1900's "Trembling with fear" Characterized by headaches,
Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.
Xenotropic Murine Leukemia Virus-Related Retrovirus: CCR Assay Development.
X. James Li, Ph.D. Cellex, Inc.. Topics  Homogeneous Biochemiluminescence Assays (HBA) and Its Use for Detection of Influenza Viral Neuraminidase (NA)
Proposed algorithm for approval of human TSE tests in Europe.
Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.
Mark Fang Stanford iGEM 08-09
CHALLENGES FACED IN THE DEVELOPMENT OF BIOSIMILARS Dr.G.Hima Bindu MD; PG dip. diabetology Asst.Professor Dept. of Pharmacology Rajiv Gandhi Institute.
Proteins are instrumental in about everything that an organism does. These functions include structural support, storage, transport of other substances,
THE STRUCTURE AND FUNCTION OF MACROMOLECULES Proteins - Many Structures, Many Functions 1.A polypeptide is a polymer of amino acids connected to a specific.
Laboratory of Cellular Hematology
Controls for Blood Septicemia Nucleic Acid Tests Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT XIX Meeting Berne, Switzerland.
1 Laboratory of Bacterial, Parasitic and Unconventional Agents (LBPUA) Research Programs Report to BPAC 13 July 2006 Site Visit by Ad Hoc Review Committee.
John Gray, Sandor Dudas and Stefanie Czub
19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.
Potency Testing for an Autologous Cellular Immunotherapy Nicole Provost, PhD VP Product Development Dendreon Corporation February 9, 2006.
TSE Agent Clearance Issues TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
Founders With the support of. 2 Letters of intent  Individual quotation, then selection by the SAB Validation by the Bureau  Full Application  Individual.
The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.
Objective 7: TSWBAT recognize and give examples of four levels of protein conformation and relate them to denaturation.
The History of Chronic Wasting Disease Dr. Trent Bollinger, CCWHC One World, One Health Symposium Sept. 29, 2004.
Rapid Molecular Diagnostic Test of HIV-1 Purified RNA from Plasma Michael M. Ling, Ph.D
Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.
BSE: World update FDA TSE Advisory Committee Gaithersburg, MD September 18, 2006 Lisa A. Ferguson, DVM Senior Staff Veterinarian USDA, APHIS, Veterinary.
Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood Jenny Zhou and Anne Ye Fan, Vermesh, et.
Specific Defenses of the Host Part 2 (acquired or adaptive immunity)
PROTEINS L3 BIOLOGY. FACTS ABOUT PROTEINS: Contain the elements Carbon, Hydrogen, Oxygen, and NITROGEN Polymer is formed using 20 different amino acids.
TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,
Proteolytic Inactivation of prions; a biological solution to TSE decontamination. Dickinson J*, Murdoch H*, Sutton JM*, Crabb, W. D.#, Bott, R#, Penet,
CHAPTER 5 THE STRUCTURE AND FUNCTION OF MACROMOLECULES Copyright © 2002 Pearson Education, Inc., publishing as Benjamin Cummings Section D: Proteins -
3S: Proteins Shireen Rudina. What do proteins do? Structure – Collagen in skin, keratin in hair and nails Signaling between cells Defend against disease.
(Bovine spongiform encephalopathy)
CHAPTER 5 THE STRUCTURE AND FUNCTION OF MACROMOLECULES
3.11 Proteins are essential to the structures and activities of life
Protein Synthesis and Protein Folding
Proteins Section 3.4.
Impact of clonal competition for peptide-MHC complexes on the CD8+ T-cell repertoire selection in a persistent viral infection by Katherine K. Wynn, Zara.
CHAPTER 5 THE STRUCTURE AND FUNCTION OF MACROMOLECULES
Fig. 1 Co-aggregation of Aβ16–22 and Aβ40 results in accelerated aggregation kinetics for Aβ40. Co-aggregation of Aβ16–22 and Aβ40 results in accelerated.
Presentation transcript:

Pronucleon TM Amplified Misfolded Protein Diagnostic Assay (AMP-D) Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc., Rockville, MD

Proprietary2 Amplified Misfolded Protein Diagnostic (AMP-D) Assay Exploits the basis of the misfolded protein disease protein conformational change A unique peptide based mimic of mechanism of disease –Specificity through amino acid sequence homology and conformational recognition of target –Sensitivity through fluorescent amplification of reaction Alpha helix to Beta sheet

Proprietary3 Association of Conformational Change with Fluorescence Conformational change in the peptide is associated with a shift in fluorescence intensity from excimer emission The ratio of relative excimer fluorescence to monomer relative fluorescence emission provides a measurement of the presence of  -sheet rich PrP TSE target substrate.

Proprietary4 Development Issues: PrP TSE Blood Tests Pronucleon™ AMP-D positive assay controls. Physical state of target Time course of target appearance in the etiology of disease Prognostic correlation of measurement to infectivity Association with other proteins and/or amyloids

Proprietary5 Development of Synthetic Assay Controls Synthetic Peptide Aggregate Control for TSE Controlled conditions for creating target substrates. Stable production and storage conditions. Amplification kinetics defined for the Adlyfe AMP-D assay.

Proprietary6 Assessment of “Natural” Controls Caughey/Silveira Laboratory of Persistent Viral Diseases (LPVD/NIAID) FlFFF size fractionated, purified PrP Sc oligomers and fibrils from Infected Hamster brains. Healthy animal brains were fractionated similarly and tested in parallel. Pronucleon™ AMP-D assay outcome on these purified fractions: Assay sensitivity is linked to: –Infectivity and PrPc-converting activity in individual fractions. –Conformation not concentration of target substrate.

Proprietary7 AMP-D TSE Assay Results with Blood Experimental disease –Clinical Hamster Squirrel monkey Murine –Preclinical Hamster Endemic disease –Clinical Sheep Bovine Human –Preclinical Sheep

Proprietary8 Defining a Model System for TSE Diagnostics Animal model bioassays can be diverse and costly. Standardization of samples and controls for confirmation of assay is a challenge. Should we pursue other options for bioassay such as cell culture? Will regulatory agencies make sample sets available with compliance standards?

Proprietary9 Performance Requirements : Steps toward TSE Ante-mortem tests Regulatory guidelines are needed for Sensitivity and Specificity in human TSE blood screening assays. Specifications for confirming TSE assay performance using animal endemic and/or controlled disease are needed. Correlation of findings with multiple tests –Cell culture-based infectivity, animal models or antibody based tests could be useful alternatives. Third party validation and site testing using a standardized battery of samples provided by regulatory authorities would be helpful.

Proprietary10 Summary The Pronucleon™ AMP-D Assay exploits the basis of the misfolded protein disease, or protein conformational change through Pronucleon™ ligands –Proof-of-principle with TSE in endemic disease states in rodents, sheep, bovine and humans –Technology concept being extended to Aβ Continued AMP-D Assay development is underway Regulatory guidelines are needed for controls and confirmation. CE marking guidelines are needed and could help formulate guidelines in other regulatory environments.

Proprietary11 Acknowledgements Adlyfe Inc. Alan Rudolph, CEO Cindy Orser, Ph.D. Renee Wegrzyn, Ph.D. Shankarama Shivaprasad, Ph.D. Jasmeet Sethi, PhD Peter Andreotti, PhD Craig Nelsen Miatta Morgan Georgetown University Anne Grosset, PhD Eugene Davidson, PhD Olga Tcherkasskaya, PhD Funding Sources DARPA, Defense Science Office NIH - NHLBI UK DEFRA Human/Murine Samples Paul Brown, MD, NIH (retired) Larisa Cervenakova, PhD MD, ARC Inga Zerr, MD, Gottingen Maurizio Pocchiari, MD, Rome VA Brain Blood Bank, LA Byron Caughey, NIAID, LPVD Monkey sCJD Thomas Kreil, PhD, Baxter Bioscience Univ. of Southern Alabama Bovine BSE Samples VLA in Weybridge UK Sheep Scrapie Samples Katherine O’Rourke, PhD (USDA) Michelle Crocheck, DVM (USDA) Moredun Institute Linda Detwiler, DVM (retired)